In addition, cancers expressing wild-type EGFR (wt-EGFR) are often insensitive to TKIs [20,21,22,23], although TKIs are potent in inhibiting the kinase activity of wt-EGFR as well [24,25,26]. Here, EGFR is linked to cancer.